TABLE 4.
Effect of Oxygen Supplementation at Baseline and Corticosteroid Use With Timing of Remdesivir Therapy on Length of Stay
| Oxygen Supplementation at Baseline | Timing of RDV From First Positive PCR Test | Total n | Length of Stay, Mean (SD) | P < 0.0001 |
|---|---|---|---|---|
| None | ≤3 d | 20 | 8.1 (3.6) | |
| >4 d | 4 | 25 (25.5) | ||
| Low flow* | ≤3 d | 179 | 11 (8.3) | |
| >4 d | 16 | 15.5 (5.2) | ||
| High flow† | ≤3 d | 150 | 18.9 (13.4) | |
| >4 d | 44 | 24 (13.7) | ||
| Mechanical ventilation | ≤3 d | 14 | 20.6 (9.2) | |
| >4 d | 29 | 20.5 (11.6) | ||
| Corticosteroid Use | Timing of RDV from first positive PCR test | Total n | Length of Stay, Mean (SD) | P = 0.0003 |
| No | ≤3 d | 215 | 13 (10.7) | |
| >4 d | 67 | 21 (12.9) | ||
| Yes | ≤3 d | 161 | 16.9 (11.7) | |
| >4 d | 32 | 23 (12.4) |
Missing data—4.6% for oxygen supplementation.
*Via nasal cannula.
†High-flow nasal cannula, continuous positive airway pressure, bilevel positive airway pressure.
RDV indicates remdesivir.